RNAi-based drug design: considerations and future directions.

Nat Rev Drug Discov

RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA.

Published: May 2024

More than 25 years after its discovery, the post-transcriptional gene regulation mechanism termed RNAi is now transforming pharmaceutical development, proved by the recent FDA approval of multiple small interfering RNA (siRNA) drugs that target the liver. Synthetic siRNAs that trigger RNAi have the potential to specifically silence virtually any therapeutic target with unprecedented potency and durability. Bringing this innovative class of medicines to patients, however, has been riddled with substantial challenges, with delivery issues at the forefront. Several classes of siRNA drug are under clinical evaluation, but their utility in treating extrahepatic diseases remains limited, demanding continued innovation. In this Review, we discuss principal considerations and future directions in the design of therapeutic siRNAs, with a particular emphasis on chemistry, the application of informatics, delivery strategies and the importance of careful target selection, which together influence therapeutic success.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11144061PMC
http://dx.doi.org/10.1038/s41573-024-00912-9DOI Listing

Publication Analysis

Top Keywords

considerations future
8
future directions
8
rnai-based drug
4
drug design
4
design considerations
4
directions years
4
years discovery
4
discovery post-transcriptional
4
post-transcriptional gene
4
gene regulation
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!